# Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis

> **NCT03576287** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tanja Todberg, MD** · enrollment: 15 (estimated)

## Conditions studied

- Prurigo Nodularis

## Interventions

- **DRUG:** Apremilast Oral Product

## Key facts

- **NCT ID:** NCT03576287
- **Lead sponsor:** Tanja Todberg, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2019-12-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2018-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03576287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03576287, "Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03576287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*